279 related articles for article (PubMed ID: 19081160)
1. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
2. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
3. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
4. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
8. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
10. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
11. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
12. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
[TBL] [Abstract][Full Text] [Related]
14. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Wu WG; Soria JC; Wang L; Kemp BL; Mao L
Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
[TBL] [Abstract][Full Text] [Related]
15. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
[TBL] [Abstract][Full Text] [Related]
16. DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B; Ma B; Yang S; Xing X; Gu R; Hu Y
Spine (Phila Pa 1976); 2009 Sep; 34(19):E677-81. PubMed ID: 19730199
[TBL] [Abstract][Full Text] [Related]
17. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.
Ouyang W; Yang C; Liu Y; Xiong J; Zhang J; Zhong Y; Zhang G; Zhou F; Zhou Y; Xie C
Int J Oncol; 2011 Dec; 39(6):1577-86. PubMed ID: 21769428
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of TRAIL and its death receptors in cervical cancer.
Maduro JH; Noordhuis MG; ten Hoor KA; Pras E; Arts HJ; Eijsink JJ; Hollema H; Mom CH; de Jong S; de Vries EG; de Bock GH; van der Zee AG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):203-11. PubMed ID: 19695437
[TBL] [Abstract][Full Text] [Related]
19. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.
Chen W; Wang X; Zhuang J; Zhang L; Lin Y
Carcinogenesis; 2007 Oct; 28(10):2114-21. PubMed ID: 17548900
[TBL] [Abstract][Full Text] [Related]
20. The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy.
Checinska A; Oudejans JJ; Span SW; Rodriguez JA; Kruyt FA; Giaccone G
Anticancer Res; 2006; 26(5B):3819-24. PubMed ID: 17094407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
